The multicenter ACCESS clinical trial suggests expanded options for blood cancer patients who struggle to find closely matched stem cell donors. The study reported that carefully selected younger donors with substantial genetic mismatches can still yield encouraging outcomes when transplant is paired with post-transplant cyclophosphamide, a regimen used to reduce graft-versus-host disease risk after mismatched transplantation.